Reata Pharmaceuticals (RETA) Receives Media Impact Score of 0.13
News articles about Reata Pharmaceuticals (NASDAQ:RETA) have trended somewhat positive recently, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Reata Pharmaceuticals earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 44.9592312569751 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Brokerages Anticipate Reata Pharmaceuticals, Inc. (RETA) Will Post Quarterly Sales of $12.58 Million (americanbankingnews.com)
- Reata Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RETA-US : August 1, 2017 (finance.yahoo.com)
- Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares (finance.yahoo.com)
- Insider Buying: Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Director Buys 8,064 Shares of Stock (americanbankingnews.com)
- Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Given Consensus Recommendation of “Buy” by Brokerages (americanbankingnews.com)
A number of research firms recently weighed in on RETA. Robert W. Baird restated an “outperform” rating and issued a $47.00 price target (up from $43.00) on shares of Reata Pharmaceuticals in a research note on Tuesday, July 25th. Stifel Nicolaus restated a “buy” rating and issued a $50.00 price target (up from $38.00) on shares of Reata Pharmaceuticals in a research note on Tuesday, July 25th. Citigroup Inc. restated a “buy” rating and issued a $87.00 price target (up from $39.00) on shares of Reata Pharmaceuticals in a research note on Tuesday, July 25th. Ladenburg Thalmann Financial Services restated a “buy” rating and issued a $61.00 price target (up from $55.00) on shares of Reata Pharmaceuticals in a research note on Wednesday, July 26th. Finally, Zacks Investment Research downgraded Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 18th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $55.83.
Shares of Reata Pharmaceuticals (NASDAQ RETA) traded up 2.82% during trading on Monday, reaching $29.54. The company had a trading volume of 145,767 shares. The stock’s market capitalization is $660.66 million. Reata Pharmaceuticals has a 12 month low of $15.17 and a 12 month high of $41.60. The stock’s 50-day moving average price is $30.77 and its 200-day moving average price is $25.85.
In other news, major shareholder A/S Novo sold 23,327 shares of the firm’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $28.67, for a total value of $668,785.09. Following the sale, the insider now directly owns 942,467 shares of the company’s stock, valued at $27,020,528.89. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director James Edward Bass purchased 8,064 shares of the stock in a transaction dated Tuesday, August 1st. The stock was acquired at an average cost of $31.00 per share, for a total transaction of $249,984.00. Following the completion of the transaction, the director now owns 67,411 shares of the company’s stock, valued at approximately $2,089,741. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 471,886 shares of company stock worth $12,541,056. 62.40% of the stock is currently owned by company insiders.
About Reata Pharmaceuticals
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
Receive News & Ratings for Reata Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.